Latest News

February 10, 2023

ECOG-ACRIN announces the Remarkable Mentor to Women in Oncology Award (nominations are due March 9)

February 9, 2023

The application period is now open for Spring Meeting Attendance Awards for minority trainees

February 6, 2023

Ongoing Trial: The INSIGNA clinical trial is testing the timing of immunotherapy alone or with chemotherapy for patients with advanced lung cancer

February 1, 2023

Ongoing Trial: The INSPIRE research study is testing a new treatment approach for patients with advanced bladder cancer

January 30, 2023

Now Enrolling: The BRIDGE research study is evaluating a new treatment approach for patients with early bladder cancer

January 24, 2023

Blinatumomab significantly improves overall survival in newly diagnosed B-ALL patients who are MRD-negative after initial treatment (study E1910)

January 5, 2023

The Winter 2023 advocacy blog Considering Clinical Trials is now available

December 20, 2022

The November/December 2022 News from ECOG-ACRIN blog is now available

December 19, 2022

Blinatumomab Plus Consolidation Chemotherapy Significantly Reduces Risk of Death in MRD-Negative B-Cell ALL


About Us

The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More


Home

Scientific Pursuits

We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More


ECOG-ACRIN by the Numbers

Home
43

Active Clinical Trials

Home
1400

Participating Institutions

Home
67

International Sites

Home
21000

Individual Members


Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).

ECOG-ACRIN Cancer Research Group